The battle between original pharmaceuticals and their generic counterparts has always been about balancing public interest with a rigorous national intellectual property regime.
This balancing act is particularly important but difficult for developing countries, such as Malaysia.
Original pharmaceutical drugs are generally protected by patents, which are essential to ensure a return on investment (in research and development, clinical studies, clinical trials), through a fixed-term market monopoly. On average, it can take between seven and 10 years for original drugs to get from the laboratory to the market. By comparison, a granted Malaysian patent confers a non-extendable 20-year monopoly, calculated from the filing date of the patent application.
Patent owners argue that, due to delays in patent prosecution and the process of regulatory approvals, this 20-year monopoly is insufficient compensation for the substantial investment committed to bring original drugs to the market. Unlike in the US or Europe, there are no provisions in Malaysian patent law for the grant of either supplementary protection certificates (SPC) or patent term extensions (PTE) to patents.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.
pharmaceuticals, generic drugs, Malaysia Patent Act